Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center

Background: Natalizumab (NTZ) and fingolimod (FTY) are second-line disease modifying treatments (DMTs) approved for Relapsing – Remitting Multiple Sclerosis (RRMS). Few studies are available on a direct comparison between NTZ and FTY, based on post-marketing experience, with conflicting results and...

Descripción completa

Detalles Bibliográficos
Autores principales: Boziki, Marina, Bakirtzis, Christos, Giantzi, Virginia, Sintila, Styliani-Aggeliki, Kallivoulos, Stylianos, Afrantou, Theodora, Nikolaidis, Ioannis, Ioannidis, Panagiotis, Karapanayiotides, Theodoros, Koutroulou, Ioanna, Parissis, Dimitrios, Grigoriadis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419322/
https://www.ncbi.nlm.nih.gov/pubmed/34497577
http://dx.doi.org/10.3389/fneur.2021.699844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419322/
https://www.ncbi.nlm.nih.gov/pubmed/34497577
http://dx.doi.org/10.3389/fneur.2021.699844

Ejemplares similares